David M. Siegel, M.D., Ph.D., chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses the feasibility of using pomalidomide to treat patients with myeloma who have become refractory to lenalidomide.
READ FULL ARTICLE ON ONCLIV.COM